David here.

On Monday morning, biotech firm Moderna (NASDAQ: MRNA) announced that its COVID-19 vaccine is 94.5% effective against the coronavirus.

I don’t have to be the one to tell you that this is incredible news. Dr. Anthony Fauci himself even called these results “as good as it gets.”

It’s the second major vaccine result to emerge in the last couple of weeks, following Pfizer’s announcement that their trial was 90% effective.

(And just a couple of days ago, Pfizer announced their final analysis showed 95% vaccine efficacy.)

Such promising results certainly have us all dreaming of what returning to normal may look like in a post-COVID world.

And besides the obvious, this news carries with it another exciting development for angel investors and venture capitalists alike:

You see, just two years ago, Moderna was a startup company.

The company was founded back in 2010 as one of the world’s most promising biotech startups.

They raised an earth-shattering $1.8 billion across four different funding rounds between 2015 and 2018. (Two of those funding rounds broke industry records.)

And in December 2018, Moderna held the largest biotech IPO in history, selling 26.3 million shares for $23 each, and raising just over $604 million.

As an angel investor and a venture capitalist, this trajectory is incredibly exciting to me.

Moderna is barely a decade old, and it’s been less than two years since it debuted on the public markets. That this company was able to achieve so much – and potentially change the course of an entire pandemic – so quickly is an incredible feat for such a relatively young company.

To me, this success is a sure sign of the value of startup investing.

Each one of Moderna’s funding rounds was led by a series of highly successful and highly wealthy venture capital firms. Of course, not everyone has the type of money that these guys have to be able to invest in these types of high-profile funding rounds.

But times have changed a whole lot since Moderna was founded.

Back in 2010, equity crowdfunding wasn’t really on anyone’s radar. It wasn’t until 2016 that everyday folks got the opportunity to invest in up-and-coming companies at a much cheaper price point.

What I’m saying is that the doors are wide open right now.

You’re in a very unique position. With just a couple of hundred dollars, you now have the chance to claim a stake in companies with the very same potential as Moderna.

And over at the Angels & Entrepreneurs Network, we’re constantly on the lookout for companies that could change the world just like they have. So far, we’ve featured startups like…

  • A company fighting climate change by turning wasted food into brand-new products…
  • A company giving the best and brightest kids in the country the chance to go to college without taking on a lifetime of student debt…
  • A company that’s helping the world’s biggest corporations reuse and recycle materials that most people would consider “unrecyclable”…
  • And so many more.

In fact, we’ve even hosted several deal showcases over the last year and a half to bring our subscribers all of the important details on these deal recommendations. Since joining the Advisory Board just a few months ago, I’ve had a great time helping to source deals for these showcases myself. The independent research team thoroughly examines them and sends these recommendations my way.

We have plenty more of these opportunities coming over the next few months… and as our Advisory Board continues to grow, I don’t expect our deal flow to slow down one bit.

In the meantime, I also wanted to turn your attention to something very similar happening over at Money Morning.

In just a few days, my colleague Shah Gilani (who you’ve met a few times before) is putting 50 different stock picks in his version of the “hot seat” to show you which ones are worth your while… and which ones aren’t.

It’s kind of like a massive deal showcase, but for the public markets.

His top picks are under-the-radar companies that are growing steadily in large markets and are already making a lot of money. Their shares are expected to keep trading at value-level prices, and in some cases, they’re paying out large dividends just for hanging onto your shares.

In my opinion, there’s really never been a better time to take advantage of opportunities like this, and it’s even easier when you have a stock market genius like Shah leading the way.

Neil and I will be back very soon with more information on this opportunity, so keep an eye on your inboxes. You don’t want to miss out on this one.

Have a great rest of your weekend!

Very best,

David Weisburd